Remote Digital Cognitive Assessment in a Trial-Ready Alzheimer’s Cohort: A Scalable Approach for Early Intervention Studies

Background: Early detection of cognitive decline in Alzheimer’s disease (AD), particularly in preclinical stages, is critical for evaluating therapeutic interventions. Traditional cognitive assessments often lack reliability and require lengthy in-person visits, limiting scalability for younger, trial-ready populations.Objectives: To evaluate the feasibility, reliability, and validity of high-frequency remote digital cognitive assessments in individuals with autosomal dominant Alzheimer’s disease (ADAD).Participants: 162 mutation carriers and non-carriers from DIAN-TU from 20 international sites (Ages 19-69 years).Measurements: Participants completed remote assessments via personal smartphones, prompted four times daily for seven days (approximately 3 minutes per session), and conventional in-clinic cognitive testing at baseline. Adherence, test–retest reliability (intraclass correlation coefficients [ICCs]), construct validity (confirmatory factor analysis), and sensitivity to clinical impairment were evaluated.Results: Average adherence was 41%. Despite this, remote measures demonstrated excellent reliability (ICCs > 0.90 after 10 sessions) and strong construct validity, with tasks loading onto memory, attention, and executive function domains. Model fit was poorer in symptomatic individuals (CDR > 0), consistent with cognitive dedifferentiation during disease progression. Both remote and traditional composites were sensitive to clinical impairment, with similar effect sizes and increasing group differences near expected symptom onset.Conclusions: High-frequency remote cognitive assessment is feasible, reliable, and valid in a relatively young international ADAD cohort. This approach offers substantial advantages for clinical trials, including reduced participant burden, improved accessibility, and enhanced reliability, supporting its integration into early-intervention studies.

Authors

Institutions

Publication Details

Published
2025-10-03
DOI
https://doi.org/10.31234/osf.io/mz62t_v1
Primary Topic
Cognitive Science and Mapping
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Remote Digital Cognitive Assessment in a Trial-Ready Alzheimer’s Cohort: A Scalable Approach for Early Intervention Studies

Tammie L.S. Benzinger, Matthew S. Welhaf, Alan E. Renton, Richard J. Perrin et al.
Cognitive Science and Mapping
article

Remote Digital Cognitive Assessment in a Trial-Ready Alzheimer’s Cohort: A Scalable Approach for Early Intervention Studies

Tammie L.S. Benzinger, Matthew S. Welhaf, Alan E. Renton, Richard J. Perrin, Yan Li, Randall John Bateman, Sarah H. Stout, David Fernando Aguillon, Johannes Levin, Jacob Bechara, William S. Brooks, Raquel Sánchez‐Valle, Jason J. Hassenstab, Suman Jayadev, Ricardo Allegri, Eric McDade, Catherine J. Mummery, Guoqiao Wang, Martin J. Sliwinski, Hannah Wilks, Andrew J. Aschenbrenner, Brian A. Gordon, Christopher H. van Dyck, Chengjie Xiong, Samhita Katteri
article en

Abstract

Background: Early detection of cognitive decline in Alzheimer’s disease (AD), particularly in preclinical stages, is critical for evaluating therapeutic interventions. Traditional cognitive assessments often lack reliability and require lengthy in-person visits, limiting scalability for younger, trial-ready populations.Objectives: To evaluate the feasibility, reliability, and validity of high-frequency remote digital cognitive assessments in individuals with autosomal dominant Alzheimer’s disease (ADAD).Participants: 162 mutation carriers and non-carriers from DIAN-TU from 20 international sites (Ages 19-69 years).Measurements: Participants completed remote assessments via personal smartphones, prompted four times daily for seven days (approximately 3 minutes per session), and conventional in-clinic cognitive testing at baseline. Adherence, test–retest reliability (intraclass correlation coefficients [ICCs]), construct validity (confirmatory factor analysis), and sensitivity to clinical impairment were evaluated.Results: Average adherence was 41%. Despite this, remote measures demonstrated excellent reliability (ICCs > 0.90 after 10 sessions) and strong construct validity, with tasks loading onto memory, attention, and executive function domains. Model fit was poorer in symptomatic individuals (CDR > 0), consistent with cognitive dedifferentiation during disease progression. Both remote and traditional composites were sensitive to clinical impairment, with similar effect sizes and increasing group differences near expected symptom onset.Conclusions: High-frequency remote cognitive assessment is feasible, reliable, and valid in a relatively young international ADAD cohort. This approach offers substantial advantages for clinical trials, including reduced participant burden, improved accessibility, and enhanced reliability, supporting its integration into early-intervention studies.

Washington University in St. Louis (US)
Foundation for the National Institutes of Health, Alzheimer's Association, Eli Lilly and Company, GHR Foundation, National Institutes of Health, Avid Radiopharmaceuticals, Janssen Pharmaceuticals
Openalex Percentile: Top 86%
Cognitive Science and Mapping
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.